JP2016505023A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505023A5
JP2016505023A5 JP2015552904A JP2015552904A JP2016505023A5 JP 2016505023 A5 JP2016505023 A5 JP 2016505023A5 JP 2015552904 A JP2015552904 A JP 2015552904A JP 2015552904 A JP2015552904 A JP 2015552904A JP 2016505023 A5 JP2016505023 A5 JP 2016505023A5
Authority
JP
Japan
Prior art keywords
composition
methylxanthine
item
leucine
theophylline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015552904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505023A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011531 external-priority patent/WO2014113404A1/en
Publication of JP2016505023A publication Critical patent/JP2016505023A/ja
Publication of JP2016505023A5 publication Critical patent/JP2016505023A5/ja
Pending legal-status Critical Current

Links

JP2015552904A 2013-01-15 2014-01-14 肺の状態の処置 Pending JP2016505023A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752909P 2013-01-15 2013-01-15
US61/752,909 2013-01-15
PCT/US2014/011531 WO2014113404A1 (en) 2013-01-15 2014-01-14 Treating pulmonary conditions

Publications (2)

Publication Number Publication Date
JP2016505023A JP2016505023A (ja) 2016-02-18
JP2016505023A5 true JP2016505023A5 (enExample) 2017-02-16

Family

ID=51210014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552904A Pending JP2016505023A (ja) 2013-01-15 2014-01-14 肺の状態の処置

Country Status (6)

Country Link
US (3) US20150359771A1 (enExample)
EP (1) EP2945616B1 (enExample)
JP (1) JP2016505023A (enExample)
CN (1) CN105101958B (enExample)
AU (1) AU2014207707B2 (enExample)
WO (1) WO2014113404A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012284267B2 (en) 2011-07-15 2017-06-29 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
JP6469015B2 (ja) 2012-11-13 2019-02-13 ニューサート サイエンシーズ， インコーポレイテッド エネルギー代謝を増大させるための組成物および方法
EP2945616B1 (en) 2013-01-15 2018-11-28 NuSirt Sciences, Inc. Treating pulmonary conditions
WO2014149280A1 (en) * 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
WO2015006465A1 (en) * 2013-07-10 2015-01-15 Ahkeo Ventures LLC Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
CA2939833A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
CN107998110A (zh) * 2018-01-11 2018-05-08 上海市普陀区中心医院 白藜芦醇用于制备治疗或缓解慢性气道炎症性疾病用药物的用途
US10830778B2 (en) * 2018-05-24 2020-11-10 C Technologies, Inc. Slope spectroscopy standards
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
US11437483B2 (en) 2020-03-05 2022-09-06 Intel Corporation Gate-all-around integrated circuit structures having dual nanoribbon channel structures

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
EP0511587A1 (en) * 1991-04-26 1992-11-04 Takeda Chemical Industries, Ltd. Slimming composition
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US20010051654A1 (en) * 1997-09-25 2001-12-13 Elliott Peter J. Treatment of inflammatory and autoimmune diseases
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
AU765909C (en) 1998-12-17 2004-09-23 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
EP1461101A4 (en) * 2001-12-07 2005-02-09 Glaxo Group Ltd DOSAGE VALVE, PHARMACEUTICAL AGENT AEROSOL-DOSER, AND METHODS THEREOF
AU2003231788B2 (en) 2002-05-17 2008-09-11 Duke University Method for treating obesity
JP4485945B2 (ja) 2002-06-26 2010-06-23 インターシア セラピューティクス，インコーポレイティド 浸透圧デリバリーシステムの最小服従型で、容積効率型ピストン
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US20060173079A1 (en) * 2003-01-10 2006-08-03 Universiteit Van Maastricht Compositions and methods for improving the condition of patients suffering from copd and other diseases
WO2005065726A1 (en) * 2003-12-30 2005-07-21 Dr. Reddy's Laboratories Ltd. Pharmaceutical composition
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2006009769A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
EP1818053A4 (en) * 2004-11-02 2008-02-27 Ajinomoto Kk MEDICINE FOR THE TREATMENT / PROPHYLAXIS OF ALLERGIC DISEASES
EP1845994B1 (en) * 2005-02-11 2009-01-21 Argenta Discovery Limited Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
EA013474B1 (ru) 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
KR20080108487A (ko) 2006-02-28 2008-12-15 트르스티스 오브 보스톤 유니버시티 대사 조절인자 및 그의 용도
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
WO2010086746A2 (en) * 2009-01-28 2010-08-05 Life Science Nutrition As Compositions and methods of treating viral infections
US20110064720A1 (en) * 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
US8173181B2 (en) * 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
EP2571499A1 (en) * 2010-05-18 2013-03-27 Mahmut Bilgic Pharmaceutical composition comprising n- acetylcysteine and a xanthine
AU2012284267B2 (en) * 2011-07-15 2017-06-29 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
EP2945616B1 (en) 2013-01-15 2018-11-28 NuSirt Sciences, Inc. Treating pulmonary conditions
WO2014149280A1 (en) * 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators

Similar Documents

Publication Publication Date Title
JP2016505023A5 (enExample)
AU2025204271A1 (en) Microcrystalline diketopiperazine compositions and methods
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
NZ603579A (en) Controlled release formulations
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
JP2011225596A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
NZ747376A (en) High dose levodopa capsules for pulmonary use
NZ606548A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
JP2013516493A5 (enExample)
GB201018289D0 (en) Treatment of respiratory disorders
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
JP2013536015A5 (enExample)
JP2013505205A5 (enExample)
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
RU2009142937A (ru) Тапентадол для лечения в связи с остеоартрозом
JP2015038135A5 (enExample)
JP2016534142A5 (enExample)
IL251413B1 (en) Composition of injectable buprenorphine
HRP20180774T1 (hr) Orodisperzibilni dezmopresin za povećanje početnog razdoblja sna neometanog s nokturijom
JP2013531041A5 (enExample)
HRP20240115T1 (hr) Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
WO2011112922A3 (en) Co-crystals and pharmaceutical formulations comprising the same
PE20091418A1 (es) Formulaciones de flibanserina
RU2013157398A (ru) Композиция